| __timestamp | ADMA Biologics, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 2983000000 |
| Thursday, January 1, 2015 | 6745968 | 3426000000 |
| Friday, January 1, 2016 | 8494742 | 3398000000 |
| Sunday, January 1, 2017 | 18092835 | 3878000000 |
| Monday, January 1, 2018 | 22502922 | 4056000000 |
| Tuesday, January 1, 2019 | 25910757 | 4381000000 |
| Wednesday, January 1, 2020 | 35050817 | 5151000000 |
| Friday, January 1, 2021 | 42896889 | 5246000000 |
| Saturday, January 1, 2022 | 52458024 | 5673000000 |
| Sunday, January 1, 2023 | 59020000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, effective cost management is crucial for sustained growth and innovation. Over the past decade, Gilead Sciences, Inc. and ADMA Biologics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences saw a steady increase in SG&A expenses, peaking at approximately $6.09 billion in 2023, reflecting a 104% rise from 2014. This growth underscores Gilead's expansive operational strategies and market reach.
Conversely, ADMA Biologics, a smaller player, experienced a dramatic 1,124% surge in SG&A expenses, reaching $59 million in 2023. This sharp increase highlights ADMA's aggressive scaling efforts and investment in market penetration. As these companies navigate the complexities of the biotech sector, their SG&A trends offer valuable insights into their strategic priorities and financial health.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Jazz Pharmaceuticals plc vs ADMA Biologics, Inc.
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV